Jupiter Neurosciences begins enrolling participants for its Phase 2a clinical trial of an innovative oral treatment for Parkinson’s

A new clinical milestone brings hope for a disease-modifying therapy that targets the biological roots of Parkinson’s rather than just managing its symptoms. Jupiter Neurosciences has officially commenced patient enrollment for its Phase 2a trial, known as the RESET study, to evaluate an investigational oral drug candidate called JOTROL. The study is a collaborative effort alongside Georgetown University and MedStar Health, with the first participant dosing expected to take place in the near future. The trial is focusing on JOTROL, which is a unique, patented micellar formulation of trans-resveratrol. Resveratrol is a natural compound renowned for its potential therapeutic qualities, but traditional formulations struggle to be absorbed effectively by the human body and often cause gastrointestinal issues. To overcome these hurdles, the developers designed a delivery system that enhances the drug's bioavailability by approximately nine-fold. This significant boost allows the active ingredient to cross into the central nervous system much more effectively, providing a realistic chance to combat the underlying cellular mechanisms of the condition. The science behind this trial focuses on three primary biological drivers of neurodegeneration: oxidative stress, mitochondrial dysfunction, and chronic neuroinflammation. Preclinical studies using established laboratory models of Parkinson's have already yielded encouraging results. In these early tests, the drug demonstrated neuroprotective effects that successfully preserved motor function, including noticeable improvements in grip strength and physical coordination. The RESET study is a multi-centre, randomised, double-blind, placebo-controlled trial. It plans to enroll thirty participants between the ages of 55 and 85 who have been diagnosed with Parkinson's and are currently stable on their standard medications. Over a twelve-week period, the participants will be split into three equal groups to receive either one of two different doses of JOTROL or a placebo. Because this is a Phase 2a trial, the primary objectives are to carefully evaluate the safety and tolerability of the drug, while also tracking how it moves through and is processed by the body. To do this, researchers will analyze blood plasma and cerebrospinal fluid. Additionally, the team will monitor secondary endpoints, measuring changes in blood energy levels and tracking key inflammatory biomarkers to see if the treatment successfully reduces inflammation in the brain. The entire study is projected for completion in the first half of 2027. While it remains an investigational drug that is not yet approved by any regulatory authority, this trial marks a crucial step forward in the decade-long research journey to find a treatment that could potentially slow or halt the progression of Parkinson's.